2025년 08월 16일 토요일
 
 
  현재위치 > 뉴스지닷컴 > Science & Technology

랜섬웨어부터 돼지도살까지... 노련해진 사기행각

 

정치

 

경제

 

사회

 

생활

 

문화

 

국제

 

과학기술

 

연예

 

스포츠

 

자동차

 

부동산

 

경영

 

영업

 

미디어

 

신상품

 

교육

 

학회

 

신간

 

공지사항

 

칼럼

 

캠페인
한살림 ‘우리는 한쌀림’ 쌀 소비 캠페인 시...
1000만원짜리 인공와우, 건강보험 지원 ‘평...
- - - - - - -
 

QPS India Successfully Completes Week-Long US FDA Regulatory Inspection

뉴스일자: 2025-05-16

NEWARK, DEL -- QPS India, a subsidiary of QPS Holdings, LLC (QPS), a GLP/GCP-compliant global full-service Contract Research Organization, has achieved another significant milestone by successfully completing an unscheduled inspection by the US Food and Drug Administration (FDA) from the 21st to the 25th of April 2025. The inspection was a systems & processes audit resulting in the site approval for all studies conducted at QPS India and submitted by sponsors for US regulatory agency approval. This approval marks the 46th successful regulatory inspection for QPS India over the past two decades, including previous audits by the US FDA, EMA, UK MHRA, WHO, ANVISA, NPRA, NABL, GCC, and CDSCO, and reinforces QPS India's unwavering commitment to the highest standards of quality, compliance, and scientific rigor.

“This outcome underscores QPS India’s focus on quality, compliance, and scientific integrity. It comes at the perfect time as we introduce specialized dermal safety services for our global clients. Our team’s unwavering efforts continue to position us as a reliable partner for regulatory-driven, high-quality research” said Dr. Kumar Ramu, Sr. Vice President & Managing Director, QPS India.

QPS India: Key Highlights

State-of-the-Art Facility:


·138-bed clinical unit, with 1,800+ Phase I and BA/BE studies completed
·PK/PD studies in patient populations
·11 LC/MS/MS instruments for bioanalysis, with 800+ bioanalytical methods developed

Comprehensive Clinical Services: End-to-end support for clinical research

·Clinical Services: Phase I to Phase IV studies
-Fully compliant with global standards, including ICH-GCP and local regulatory requirements
·Dermatology Safety Study Expertise
-Skin Irritation (Cumulative Irritation Patch Test - CIPT) studies
-Sensitization (Human Repeat Insult Patch Test - HRIPT) studies
·Bioanalytical Services: Advanced analysis using cutting-edge technology
·Medical Writing: High-quality documentation for regulatory compliance
·Clinical Data Management: Efficient handling of clinical data
·Pharmacokinetics and Statistical Analysis: Robust statistical models on comparative trials for FDA and EMA submissions
·Quality Assurance and Regulatory Support: Proven track record with successful submissions to global regulatory authorities (including FDA and EMA)

QPS India, established in Hyderabad in 2004, is a subsidiary of QPS Holdings, LLC, a GLP/GCP-compliant global full-service CRO providing discovery, preclinical, bioanalysis, and clinical research services to pharma and biotech clients for the past 30 years. With a robust presence across 9 locations worldwide, including the USA (Delaware - Headquarters, Miami & Missouri), Europe (Austria & The Netherlands), Asia (Taiwan, China & India), and Australia (Melbourne), QPS accelerates pharmaceutical breakthroughs by delivering custom-built research services in Pharmacology, Toxicology, DMPK, Bioanalysis, Translational Medicine, Leukopaks and Cell Therapy Products, Clinical Trials, and Clinical Research Services.



 전체뉴스목록으로

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
Bentley Systems Announces Finalists for the 2025 Going Digital Awards
LG To Introduce Advanced AI Home Innovations At IFA 2025
MMCA×LG OLED Series Kicks Off to Bring Digital Art Closer to the Public
AppLogic Networks Secures Commitment from Leading MSP to Unlock New Revenue Paths with Edge-Ready, AI-Driven QoE Platform
SecurityBridge Acquires CyberSafe To Deliver Contextual SSO, MFA, And Passwordless Authentication To SAP Users
Kioxia Commences Sample Shipments of 9th Generation BiCS FLASHTM 512Gb TLC Devices

 

KnowBe4 Delivers AI-Driven Email Security to Small and Medium Business...
Cisco Takes Licence to the Sisvel Wi-Fi 6 Patent Pool
HistoSonics’ Edison Histotripsy System Gains Great Britain Early Mark...
Omdia: Cloud Platforms Drive $12.9bn Games Market Ecosystem
Latest Mouser Series Navigates the Balance of AI and Human Expertise i...
DNP: Operational Launch of 2,500 mm-Width Coating Line to Enhance Prod...
ExaGrid Releases Version 7.3.0

 


공지사항
뉴스지 한자 표기에 대만식 음차 표기 '纽斯集 니우시지' 병기
베네프롬 베네인투 중문 표기 宝乃福牧 宝乃因托(寶乃福牧 寶...
미디어아우어 Mediaour 媒体我们 媒體我們 MO 엠오 媒我 媒我
알리우브 Alliuv 阿备: 阿联有备, 알뜰 Althle 阿特益
알리알 Allial 중문 표기 阿利尔 阿利爾
뉴퍼스트 New1st 중문 표기 纽壹新(번체 紐壹新), N1 纽1
엔코스모스 : 이씨 'EnCosmos : EC' 중문 표기 以宙
아이디어론 Idearon 중문 표기 以迪论 以迪論
바이오이니 Bioini 중문 표기 必药研 必藥硏
오스프롬 Ausfrom 奥斯福牧, 웰프롬 Welfrom 卫福牧
에너프롬 Enerfrom 额能福牧 에너유비 Eneruv 额能有备
알프롬 Alfrom 중문 표기 阿尔福牧 阿爾福牧

 

회사소개 | 인재채용 | 이용약관 | 개인정보취급방침 | 청소년보호정책 | 책임한계와 법적고지 | 이메일주소무단수집거부 | 고객센터

기사제보 이메일 news@newsji.com, 전화 050 2222 0002, 팩스 050 2222 0111, 주소 : 서울 구로구 가마산로 27길 60 1-37호

인터넷뉴스서비스사업등록 : 서울 자00447, 등록일자 : 2013.12.23., 뉴스배열 및 청소년보호의 책임 : 대표 CEO

Copyright ⓒ All rights reserved..